|Mr. Mark Christopher Capone||Chief Exec. Officer, Pres and Director||1.54M||N/A||55|
|Mr. R. Bryan Riggsbee||Chief Financial Officer, Exec. VP and Treasurer||590.53k||N/A||46|
|Dr. Jerry S. Lanchbury Ph.D.||Chief Scientific Officer||706.94k||2.95M||58|
|Mr. Richard M. Marsh Esq.||Exec. VP, Gen. Counsel and Sec.||708.87k||1.48M||59|
|Mr. Bernard F. Tobin||Pres of Crescendo Bioscience Inc||615.52k||N/A||60|
Myriad Genetics, Inc., a personalized medicine company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. It operates through two segments, Diagnostics and Other. The Diagnostics segment primarily provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease; identify a patients likelihood of responding to drug therapy; guide a patients dosing to ensure optimal treatment; and assess a patients risk of disease progression and disease recurrence. The Other segment provides testing products and services to the pharmaceutical, biotechnology, and medical research industries; and research and development, and clinical services for patients. Its molecular diagnostic DNA sequencing tests include myRisk Hereditary cancer, a test for hereditary cancers; BRACAnalysis and BART, which are tests for hereditary breast and ovarian cancers; BRACAnalysis CDx test for use in identifying ovarian cancer patients with suspected deleterious germline; and Tumor BRACAnalysis CDx test that is used to predict DNA damaging agents, such as platinum based chemotherapy agents and poly ADP ribose inhibitors. The company also provides COLARIS test for colorectal and uterine cancers; COLARIS AP test for colorectal cancer; Vectra DA protein detection test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for prostate cancer; EndoPredict RNA expression test for breast cancer; myPath Melanoma RNA expression test for diagnosing melanoma; myChoice homologous recombination deficiency (HRD) test to measure three modes of HRD; and myPlan lung cancer, an RNA expression test for lung cancer. Myriad Genetics, Inc. has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Myriad Genetics, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 7. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 8.